Muzammil Mansuri
Chairman bei Click Therapeutics, Inc.
Profil
Muzammil M.
Mansuri currently works at Click Therapeutics, Inc., as Chairman from 2021, Charm Therapeutics Ltd., as Director, Project Beacon Covid-19 LLC, as Executive Director, Orsobio, Inc., as Director, CHARM Therapeutics, Inc., as Director, and Impresa Management LLC, as Venture Partner from 2020.
Mr. Mansuri also formerly worked at BIKAM Pharmaceuticals, Inc., as President & Chief Executive Officer, Gilead Connecticut, Inc., as Chairman & Chief Executive Officer from 2007 to 2010, Adaptive Therapeutics, Inc., as Executive Chairman, Bristol Myers Squibb Co., as Director-Central Chemistry, Sequoia Pharmaceuticals, Inc., as Director, BG Medicine, Inc., as Director, AVEO Pharmaceuticals, Inc., as Director, Gilead Sciences, Inc., as SVP-Research & Development Strategy from 2010 to 2016, Sanofi, as Executive VP-Strategy & Business Development, JSB-Partners LP, as Senior Advisor, GPC Biotech, Inc., as Chief Operating Officer & Executive Vice President, Flagship Pioneering, as General Partner from 2002 to 2007, and Shell Research Ltd., as Research Scientist.
Mr. Mansuri received his doctorate degree from The Trustees of Columbia University in The City of New York, doctorate degree from the University of California, Los Angeles, and undergraduate degree and doctorate degree from University College London.
Aktive Positionen von Muzammil Mansuri
| Unternehmen | Position | Beginn |
|---|---|---|
Click Therapeutics, Inc.
 Click Therapeutics, Inc. Packaged SoftwareTechnology Services Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for people with unmet medical needs. The company is headquartered in New York, NY. | Chairman | 07.04.2021 |
Impresa Management LLC
 Impresa Management LLC Investment ManagersFinance Impresa Management LLC(Impresa Management) is a Private Equity/Venture Capital firm, a subsidiary of Devonshire Investors LLC founded in 1946.The firm is headquartered in Boston. | Private Equity Investor | 01.01.2020 |
Project Beacon Covid-19 LLC
 Project Beacon Covid-19 LLC Miscellaneous Commercial ServicesCommercial Services Part of Ginkgo Bioworks Holdings, Inc., Project Beacon Covid-19 LLC is a social benefit organization founded in 2020. The private company is based in Boston, MA. The company's mission is to support the scaling of COVID-19 testing by improving capacity, availability, access, and affordability. Project Beacon Covid-19 was acquired by Ginkgo Bioworks Holdings, Inc. on January 19, 2022. | Director/Board Member | - |
Charm Therapeutics Ltd.
 Charm Therapeutics Ltd. BiotechnologyHealth Technology Charm Therapeutics Ltd. is a British London-based company that is discovering and developing small molecule medicines using its proprietary 3D deep learning-enabled platform, Dragonfold. The company aims to create life-changing therapies for difficult-to-drug targets in cancer and other disease areas. Charm Therapeutics has raised $70 million to date and is supported by high-quality international investors, including Orbimed, F-Prime Capital, General Catalyst, Khosla Ventures, Bristol Myers Squibb, NVIDIA, and Grep-VC. The company was founded in 2021 by Laksh Aithani and David Baker, with Laksh Aithani serving as the CEO since then. | Director/Board Member | - |
OrsoBio Inc
 OrsoBio Inc Miscellaneous Commercial ServicesCommercial Services Orsobio, Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies to treat obesity and other severe metabolic disorders, such as type 2 diabetes, NASH, and severe dyslipidemias. The company is based in Palo Alto, CA. The company has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism. Orsobio has a team of physicians and scientists who are dedicated to developing therapies to treat organ failure in patients with severe metabolic disorders. The company was founded by Mani Subramanian, who has been the CEO since incorporation. | Director/Board Member | - |
| Charm Therapeutics, Inc. | Director/Board Member | - |
Ehemalige bekannte Positionen von Muzammil Mansuri
| Unternehmen | Position | Ende |
|---|---|---|
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01.02.2016 |
Gilead Connecticut, Inc.
 Gilead Connecticut, Inc. Pharmaceuticals: MajorHealth Technology Gilead Connecticut, Inc. manufactures pharmaceuticals and biotechnology chemicals. The firm develops a pipeline of small molecule therapeutics for multiple oncology and immunology-based indications. It focuses on the development of novel kinase inhibitors for the treatment of cancer, autoimmune, and inflammatory diseases. The company was founded in 2000 and is headquartered in Foster City, CA. | Chief Executive Officer | 01.01.2010 |
Flagship Pioneering
 Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Corporate Officer/Principal | 31.12.2007 |
| ░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
| ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Ausbildung von Muzammil Mansuri
| The Trustees of Columbia University in The City of New York | Doctorate Degree |
| University of California, Los Angeles | Doctorate Degree |
| University College London | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| GILEAD SCIENCES, INC. | Health Technology |
| SANOFI | Health Technology |
| BG MEDICINE, INC. | Health Technology |
| Private Unternehmen | 15 |
|---|---|
Sequoia Pharmaceuticals, Inc.
 Sequoia Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sequoia Pharmaceuticals discovers and develops unique treatments for viral diseases including HIV/AIDS and HCV-induced hepatitis with a focus on the growing global problem of drug-resistant disease. Most new anti-viral drugs were designed to block the most prevalent form of a pathogen, but these drugs become less potent due to the emergence of drug-resistant mutations. Sequoia's is to discover and develop new antiviral which are active against the most prevalent form of the virus but also anticipates the emergence of drug resistance forms thereby maintaining potency over time. Sequoia's differentiating approach is to identify a constellation of atomic interaction points which are necessary and sufficient for enzymatic function. Sequoia's protease inhibitors have been designed to interact preferentially with only these atoms, thus allowing non-critical mutations to occur without resulting in a decrease in drug potency. The foundation of Sequoia's novel Resistant-Repellent™ technology is a drug discovery tool that enhances the efficiency with which drugs are designed. It is based on an understanding of the chemical and physical nature of the molecular targets, the enzymes and receptors to which drugs bind, combined with an understanding of the molecular mechanisms that cause drug resistance. Sequoia is also discovering and developing a unique series of pharmacokinetic enhancers (PKEs) to work in combination with its own, and its partners', antiviral therapies. These sets of molecules improve the PK of existing therapeutics and reduce interpatient variability. This represents a unique approach to an important need in HIV treatment today. Sequoia is also looking to extend this novel PKE approach to other areas. Its PKEs are designed to inhibit a particular CYP isozyme and therefore change the metabolism of a co-administered therapeutic agent. The combination of PK Enhancer and the therapeutic agent enables reduced dosage and less frequent administration of the therapeutic agent. | Health Technology |
JSB-Partners LP
 JSB-Partners LP Investment Banks/BrokersFinance JSB-Partners LP offers specialized investment banking and advisory services to biotechnology and pharmaceutical companies. Its services include product partnerships, mergers and acquisitions, private placements and public underwritings. The company was founded by Wolfgang Rudolph Ralph Stoiber in 1999 and is headquartered in Boston, MA. | Finance |
BIKAM Pharmaceuticals, Inc.
 BIKAM Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology BIKAM Pharmaceuticals, Inc. develops ophthalmic pharmaceuticals products. It focuses on the discovery and development of novel drugs for degenerative diseases of the eye. The company was founded on June 12, 2007 by Shalesh Kaushal and is headquartered in Lexington, MA. | Health Technology |
Click Therapeutics, Inc.
Click Therapeutics, Inc. Packaged SoftwareTechnology Services Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for people with unmet medical needs. The company is headquartered in New York, NY. | Technology Services |
GPC Biotech, Inc.
 GPC Biotech, Inc. Drugstore ChainsRetail Trade GPC Biotech, Inc. discovers and develops anticancer drugs through discovery technologies and development approaches. It is a mechanism-based drug discovery and development company focused on treatments for cancer and fungal infections. The company is a wholly owned subsidiary of GPC Biotech AG. GPC Biotech was founded in 1992 and is located in Waltham, MA. | Retail Trade |
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Gilead Connecticut, Inc.
Gilead Connecticut, Inc. Pharmaceuticals: MajorHealth Technology Gilead Connecticut, Inc. manufactures pharmaceuticals and biotechnology chemicals. The firm develops a pipeline of small molecule therapeutics for multiple oncology and immunology-based indications. It focuses on the development of novel kinase inhibitors for the treatment of cancer, autoimmune, and inflammatory diseases. The company was founded in 2000 and is headquartered in Foster City, CA. | Health Technology |
AVEO Pharmaceuticals, Inc.
 AVEO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA. | Health Technology |
Adaptive Therapeutics, Inc.
 Adaptive Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Adaptive Therapeutics, Inc. develops pharmaceutical products. It develops drugs for applications in anti-bacterial, fungal, viral, and cancer therapeutics. The company was founded in 2002 and is headquartered in San Diego, CA | Health Technology |
Shell Research Ltd.
 Shell Research Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Shell Plc, Shell Research Ltd. is a British company that provides business support services. The private company is based in London, UK. | Commercial Services |
Impresa Management LLC
Impresa Management LLC Investment ManagersFinance Impresa Management LLC(Impresa Management) is a Private Equity/Venture Capital firm, a subsidiary of Devonshire Investors LLC founded in 1946.The firm is headquartered in Boston. | Finance |
Charm Therapeutics Ltd.
Charm Therapeutics Ltd. BiotechnologyHealth Technology Charm Therapeutics Ltd. is a British London-based company that is discovering and developing small molecule medicines using its proprietary 3D deep learning-enabled platform, Dragonfold. The company aims to create life-changing therapies for difficult-to-drug targets in cancer and other disease areas. Charm Therapeutics has raised $70 million to date and is supported by high-quality international investors, including Orbimed, F-Prime Capital, General Catalyst, Khosla Ventures, Bristol Myers Squibb, NVIDIA, and Grep-VC. The company was founded in 2021 by Laksh Aithani and David Baker, with Laksh Aithani serving as the CEO since then. | Health Technology |
Project Beacon Covid-19 LLC
Project Beacon Covid-19 LLC Miscellaneous Commercial ServicesCommercial Services Part of Ginkgo Bioworks Holdings, Inc., Project Beacon Covid-19 LLC is a social benefit organization founded in 2020. The private company is based in Boston, MA. The company's mission is to support the scaling of COVID-19 testing by improving capacity, availability, access, and affordability. Project Beacon Covid-19 was acquired by Ginkgo Bioworks Holdings, Inc. on January 19, 2022. | Commercial Services |
OrsoBio Inc
OrsoBio Inc Miscellaneous Commercial ServicesCommercial Services Orsobio, Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies to treat obesity and other severe metabolic disorders, such as type 2 diabetes, NASH, and severe dyslipidemias. The company is based in Palo Alto, CA. The company has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism. Orsobio has a team of physicians and scientists who are dedicated to developing therapies to treat organ failure in patients with severe metabolic disorders. The company was founded by Mani Subramanian, who has been the CEO since incorporation. | Commercial Services |
| Charm Therapeutics, Inc. |
